Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Guangzhou Kemrocmed Co. Ltd. is currently navigating the patent prosecution process within the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action, which is assigned to 1 distinct art unit. This indicates a narrow technical focus for the current filing, likely centered on a specific biological or pharmaceutical innovation. By operating within 1 distinct art unit, the company can tailor its arguments to the specific examination standards and precedents of that technical group.
The prosecution is overseen by 1 distinct examiner, LEE, CHIHYI NMN. As the busiest examiner for this portfolio, he is responsible for the 1 pending office action currently active. This means the company's current patent prospects in this area depend on the review of this individual. Practitioners should analyze the past decisions and preferences of LEE, CHIHYI NMN to better anticipate the trajectory of the application. The presence of 1 pending office action suggests a highly targeted approach to intellectual property within the Biotechnology & Pharmaceuticals sector, requiring precise and well-supported technical responses.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, CHIHYI NMN | 1 | 33.3% | +61.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18668422 | Nitrogen Oxide Donors of Beraprost Derivative and the Pharmaceutical Compositions with the Use Thereof | LEE, CHIHYI NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18668422 | Nitrogen Oxide Donors of Beraprost Derivative and the Pharmaceutical Compositions with the Use Thereof | LEE, CHIHYI NMN | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18668422 | Nitrogen Oxide Donors of Beraprost Derivative and the Pharmaceutical Compositions with the Use Thereof | LEE, CHIHYI NMN | 1628 | §103§112 | Non-Final OA | — | Pending | May 20, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGuangzhou Kemrocmed Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Chihyi Nmn Lee has the most, with 1 of Guangzhou Kemrocmed Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.